LC Hanker

T cell marker metagene predicts a favourable prognosis in estrogen receptor negative and Her2 positive breast cancers.

Achim Rody, Eugen Ruckhaeberle, Uwe Holtrich et al. · Cancer Research · 2009 · 49 citations

Medicine, Molecular Biology, Oncology +17

Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.

Günter Emons, P. Harter, Jalid Sehouli et al. · Journal of Clinical Oncology · 2010 · 19 citations

Medicine, Oncology, Pharmacology +17

820TiP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC)

Mansoor Raza Mirza, Robert L. Coleman, LC Hanker et al. · Annals of Oncology · 2021 · 12 citations

Medicine, Oncology, Pharmacology +11

Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.

Christian Marth, Jérôme Alexandre, LC Hanker et al. · Journal of Clinical Oncology · 2011 · 10 citations

Medicine, Oncology, Pharmacology +17